Patrick W. Gray has spent 30 years in the biotechnology industry.  Significant accomplishments include the first cloning of Hepatitis B surface antigen, multiple Interferon-alpha genes, Interferon-gamma, Lymphotoxin (TNF-beta), Bactericidal Permeability Increasing Protein, LPS Binding Protein, Platelet Activating Factor Acetylhydrolase, CCR5 (subsequently shown to be the HIV co-receptor), and Macrophage Derived Chemokine.  Five of these recombinant products are approved human pharmaceuticals or were in clinical trials.  Dr. Gray has over 40 U.S. patents on 20 different technologies and more than 100 scientific publications. Dr. Gray was a Senior Scientist at Genentech, Vice President of Science at ICOS, Vice President of Research at Macrogenics, and CEO/President at Nura.
 
Currently Dr. Gray is the Chief Scientific Director and is responsible for the scientific evaluation of new company opportunities and also aids the scientific direction of Accelerator-financed companies.